RA with anti-TNF-α Rx. | Healthy control | ||
---|---|---|---|
Moderate-good responders (n= 36) | Non- responders (n= 12) | (n= 12) | |
Mean age, years | 50.4 ± 14.5 | 49.3 ± 10.8 | 47.6 ± 8.1 |
Female (%) | 29 (80.6%) | 10 (83.3%) | 10 (83.3%) |
Disease duration, years | 5.44 ± 2.42 | 5.37 ± 2.37 | NA |
RF positivity (%) | 30 (83.3%) | 11 (91.6%) | NA |
Anti-CCP positivity (%) | 29 (80.6%) | 10 (83.3%) | NA |
ESR (mm/1st hr) | 48.9 ± 25.4 | 63.8 ± 24.4 | NA |
DAS-28 | 7.18 ± 0.74 | 7.33 ± 0.94 | NA |
Daily steroid dose (mg) | 6.5 ± 2.1 | 6.9 ± 2.4 | NA |
TNF-α inhibitors | |||
Etanercept (n = 14) | 10 (71.4%) | 4 (28.6%) | NA |
Adalimumab (n = 34) | 26 (76.5%) | 8 (23.5%) | NA |
Used DMARDs | |||
Methotrexate | 33 (91.7%) | 11 (91.6%) | NA |
Sulfasalazine | 31 (86.1%) | 10 (83.3%) | NA |
Hydroxychloroqine | 32 (88.9%) | 10 (83.3%) | NA |
Ciclosporine | 14 (38.9%) | 5 (41.7%) | NA |